The filing content is cut off and appears incomplete, but there is sufficient substantive disclosure content to produce an article. Let me work with what is available.

Rapport Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, reporting on its financial condition and operations as a clinical-stage biotechnology company.

Key Highlights

  • Shares outstanding: As of August 3, 2026, the registrant had 47,978,286 shares of common stock, $0.001 par value per share, outstanding.
  • Exchange listing: Common stock trades on The Nasdaq Global Market under the symbol RAPP.
  • Company classification: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Operating history: The company disclosed it is "a clinical-stage biotechnology company with a limited operating history" and has "incurred significant financial losses since our inception."
  • Funding dependency: According to the filing, the company "will require additional funding in order to finance operations."
  • Key license relationship: The filing references an intellectual property license with Janssen Pharmaceutical NV and a license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd.

Rapport Therapeutics Discloses Clinical-Stage Status and Funding Needs for Q2 2026

Rapport Therapeutics, Inc. (Nasdaq: RAPP), headquartered at 99 High Street, Suite 2100, Boston, MA 02110, submitted its quarterly report covering the period ended June 30, 2026. The filing was made under Commission File Number 001-42121 and covers the company's financial statements, management discussion, and risk disclosures as required under Section 13 or 15(d) of the Securities Exchange Act of 1934.

According to the filing, the company is a clinical-stage biotechnology company focused on product candidates based on its RAP technology platform. The registrant disclosed that it has "incurred significant financial losses since our inception" and anticipates continuing to incur such losses "for the foreseeable future." The filing further states that the company "will require additional funding in order to finance operations," and that if it is "unable to raise capital when needed, or on acceptable terms," it could be "forced to delay, reduce or eliminate our product development programs or commercialization efforts."

The filing contains forward-looking statements, which the company states are subject to known and unknown risks, uncertainties, and other factors that "may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements." Key areas of forward-looking disclosure include the development of product candidates, clinical trial progress, regulatory approvals, and the sufficiency of existing cash, cash equivalents, and short-term investments to fund future operating expenses and capital expenditure requirements. The company noted it does not plan to publicly update or revise any forward-looking statements contained in the report except as required by applicable law.

What Was Disclosed

Rapport Therapeutics filed its quarterly report for the period ended June 30, 2026, disclosing its status as a clinical-stage company with ongoing financial losses, a need for additional capital, and 47,978,286 shares of common stock outstanding as of August 3, 2026.